BioPharmaTrend
Latest News
All Topics
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Newsletter
Login/Join
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
back to Directory

Berg Health (acquired by BPGbio)

Berg Health logo

Website
https://berghealth.com/
Founded
2006
Patents
12
Clinical Trials
10
Publications
1207

Technologies

AI Companies (Drug Discovery) Pharmaceutical and Drug Discovery

BERG is a Boston-based biopharma company focused on taking a bold “back to biology” approach to therapeutic discovery using its unique AI-based Interrogative Biology® platform.

This platform combines patient biology and artificial intelligence-based analytics to engage the differences between healthy and disease environments. The patient’s own biology drives the platform’s results and guides us in the discovery and development of drugs, diagnostics and healthcare applications. Our platform utilizes patient population health data to bring actionable Patient IntelligenceTM to precision medicine applications. This means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems.


Posts Mentioning This Company

Top AI Drug Discovery Companies Transforming the Pharma Industry

Tech-First Companies Take the Lead in AI Drug Discovery

Nov. 27, 2023  
In recent news, Recursion (NASDAQ: RXRX), a prominent clinical stage TechBio firm, has announced the signing of agreements to acquire Cyclica and Valence, two companies with expertise in AI-enabled drug discovery. These acquisitions strengthen Recursion's position in computational chemistry, machine learning, and artificial intelligence, enhancing its technology-enabled drug discovery capabilities …
Artificial Intelligence Yields Early Results in Drug Discovery

Artificial Intelligence Yields Early Results in Drug Discovery

April 7, 2019  
A historically significant milestone has just been reached by Oxford, UK-based Exscientia, which used its artificial intelligence (AI)-based drug discovery platform Centaur Chemist™ to deliver the first drug candidate in the framework of their multiyear collaboration with GSK. This AI-derived small molecule is a highly potent in vivo active substance …
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development

 

R&D Platform

Analyze data from patient samples in both healthy and diseased states to generate novel biomarkers and therapeutic targets. Allows researchers to: Generate therapeutic targets from biological data in an unbiased way, and implement personalized medicine at scale.

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Newsletter
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.